ESMO 2025 – Tubulis keeps the NaPi2b dream alive
The first TUB-040 data come just after Tubulis raised €308m.
ESMO 2025 – J&J brings a new Rybrevant use into the fold
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
ESMO 2025 – Lilly overshadows Astra’s folate reveal
The battle intensifies as LY4170156 matches torvuta-S with activity in FRα <25% expresers.
ESMO 2025 – Padcev plus Keytruda sets the perioperative bar
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
ESMO 2025 – Celcuity fights for a share of the breast cancer market
Alongside full PIK3CA wild-type data, Celcuity sets the bar for gedatolisib's PIK3CA-mutant readout.
ESMO 2025 – Enhertu’s perioperative Destiny beckons
Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.
ESMO 2025 – Roche sticks it to its SERD rivals
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
ESMO 2025 – synthetic lethality leaves much to prove
Artios, Synnovation and Novartis show mere glimmers of activity.
